Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Otonomy Inc    OTIC

OTONOMY INC (OTIC)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
5.6(c) 5.7(c) 5.7(c) 5.7(c) 5.8(c) Last
522 546 253 388 154 004 180 719 440 640 Volume
+5.66% +1.79% 0.00% 0.00% +1.75% Change
More quotes
Financials ($)
Sales 2017 1,46 M
EBIT 2017 -92,8 M
Net income 2017 -91,3 M
Finance 2017 54,0 M
Yield 2017 -
Sales 2018 7,90 M
EBIT 2018 -70,8 M
Net income 2018 -70,2 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 83,8x
Capi. / Sales2018 22,3x
Capitalization 176 M
More Financials
Company
Otonomy, Inc. engages in the research, development, and manufacture of biopharmaceutical products.The company portfolio includes therapeutics for diseases and disorders of the ear such as otitis media, acute otitis externa, balance disorders, Ménière's disease, tinnitus, cisplatin-induced hearing... 
More about the company
Surperformance© ratings of Otonomy Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on OTONOMY INC
02/08OTONOMY : to Present at ARO Annual MidWinter Meeting
AQ
02/06Otonomy Announces Multiple Presentations for Hearing Loss and Tinnitus Progra..
GL
01/10OTONOMY, INC. (NASDAQ : OTIC) Files An 8-K Results of Operations and Financial C..
AQ
01/09OTONOMY, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
01/09Otonomy Provides Corporate and Product Pipeline Update
GL
01/04Otonomy to Present at the J.P. Morgan Healthcare Conference
GL
2017BIOCENTURY - MANAGEMENT TRACKS : Vivus, Peregrine
AQ
2017OTONOMY, INC. (NASDAQ : OTIC) Files An 8-K Departure of Directors or Certain Off..
AQ
2017OTONOMY, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2017OTONOMY : Announces Plan to Focus on Development of Drug for Ménière’s Dis..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02:30p$OTIC, $GWPH - Otonomy #OTIC & GW Pharmaceuticals PLC- #GWPH Financia.. 
02/10Otonomy Inc $OTIC Shares Bought by Dimensional Fund Advisors LP  
02/07Report: Developing Opportunities within Discovery Communications, Otonomy, Ma.. 
02/06Otonomy Announces Multiple Presentations for Hearing Loss and Tinnitus Progra.. 
01/31Get the latest news and updates for $DCO $DXPE $DVAX $GPOR $OTIC automaticall.. 
More tweets
Qtime:51
News from SeekingAlpha
01/12Otonomy (OTIC) Presents At 36th Annual J.P. Morgan Healthcare Conference - Sl.. 
2017NASDAQ BIOTECH INDEX : 54 to be added, 15 removed 
2017PREMARKET GAINERS AS OF 9 : 05 am 
2017Otonomy drops support for Otiprio to sharpen focus on pipeline development; s.. 
2017Otonomy's (OTIC) CEO David Weber on Q3 2017 Results - Earnings Call Transcrip.. 
Chart OTONOMY INC
Duration : Period :
Otonomy Inc Technical Analysis Chart | OTIC | US68906L1052 | 4-Traders
Technical analysis trends OTONOMY INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 9,75 $
Spread / Average Target 68%
EPS Revisions
Managers
NameTitle
David A. Weber President, Chief Executive Officer & Director
Jay B. Lichter Chairman
Paul E. Cayer Chief Financial, Business & Accounting Officer
Robert Michael Savel Chief Technical Officer
Katherine M. Bishop Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
OTONOMY INC2.70%173
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055